Accession Number:

ADA612883

Title:

Prostate Cancer Clinical Trials Group - The University of Michigan Site

Descriptive Note:

Final rept. 1 Apr 2009-31 Mar 2014

Corporate Author:

MICHIGAN UNIV ANN ARBOR

Personal Author(s):

Report Date:

2014-06-01

Pagination or Media Count:

198.0

Abstract:

Purpose The objective of the Prostate Oncology Program at the University of Michigan is to understand the biology of prostate cancer and to use this information to develop new tools for the detection, diagnosis, prevention, treatment and survivorship of prostate cancer. Scope The scope is to translate scientific observations on the biology of prostate cancer into therapeutic clinical trials which incorporate correlative measures for assessing response, progression and therapeutic effect. Major progress. The focus of the University of Michigan during these five years of the DOD-PCCTC has been to maintain and improve the necessary infrastructure to facilitate the execution of multicenter trials a process that includes data sharing, opening and accruing to Consortium trials, disseminating initial findings from PCCTC-DOD trials to the Consortium and larger research community, as well as introducing important and novel translational clinical trials to the DOD-PCCTC for member participation. Results. The University of Michigan has introduced ten trials for Consortium participation during the five year period of the 2009 CCA award 412009- 3312014, three of which stem from scientific data generated by our Prostate Cancer scientists. Seven trials were coordinated by the University of Michigan and two of these trials investigated NCI agents. Accrual is completed for fourteen trials and clinical and biological samples analysis is near completion resulting in several abstracts. In the fifth year, a poster was presented at the 2013 ASCO Annual meeting C11-079, XL184, an abstract at the 2014 ASCO Genitourinary Cancers Symposium c12-111, PSMA ADC 2301 and three abstracts were accepted for presentation at the Poster Highlights Session Genitourinary Prostate Cancers at the 2014 ASCO Annual Meeting one additional abstract were accepted as publication-only abstract.We have had several manuscriptspublishedsubmitted during this final fifth year of the funding period.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE